JP2016510594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510594A5 JP2016510594A5 JP2015561628A JP2015561628A JP2016510594A5 JP 2016510594 A5 JP2016510594 A5 JP 2016510594A5 JP 2015561628 A JP2015561628 A JP 2015561628A JP 2015561628 A JP2015561628 A JP 2015561628A JP 2016510594 A5 JP2016510594 A5 JP 2016510594A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- heparanase
- cells
- specific
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772591P | 2013-03-05 | 2013-03-05 | |
| US61/772,591 | 2013-03-05 | ||
| PCT/US2014/020936 WO2014138315A1 (en) | 2013-03-05 | 2014-03-05 | Heparanase expression in human t lymphocytes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510594A JP2016510594A (ja) | 2016-04-11 |
| JP2016510594A5 true JP2016510594A5 (enExample) | 2017-04-06 |
Family
ID=50397277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561628A Ceased JP2016510594A (ja) | 2013-03-05 | 2014-03-05 | Ｔリンパ球におけるヘパラナーゼの発現 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160017302A1 (enExample) |
| EP (1) | EP2964253A1 (enExample) |
| JP (1) | JP2016510594A (enExample) |
| CN (1) | CN105407914A (enExample) |
| AU (1) | AU2014225708B2 (enExample) |
| CA (1) | CA2904236A1 (enExample) |
| HK (1) | HK1220111A1 (enExample) |
| WO (1) | WO2014138315A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| KR102723492B1 (ko) | 2015-04-23 | 2024-10-29 | 베일러 칼리지 오브 메디신 | 생체내 지속성 및 치료학적 활성 및 이의 증식을 위한 nkt-세포 서브세트 |
| WO2016187459A1 (en) | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| WO2016196388A1 (en) * | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| TWI812584B (zh) * | 2015-10-30 | 2023-08-21 | 美國加利福尼亞大學董事會 | 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法 |
| WO2017117521A1 (en) * | 2015-12-31 | 2017-07-06 | Berkeley Lights, Inc. | Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| CA3048645A1 (en) | 2016-12-30 | 2018-07-05 | The Regents Of The University Of California | Methods for selection and generation of genome edited t cells |
| US20200016207A1 (en) * | 2017-03-20 | 2020-01-16 | Baylor College Of Medicine | TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLS |
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| US12043667B2 (en) | 2019-05-04 | 2024-07-23 | Inhibrx Biosciences, Inc. | CLEC12a binding polypeptides and uses thereof |
| CA3148027A1 (en) | 2019-05-08 | 2020-11-12 | 2Seventy Bio, Inc. | Cll-1 targeted immunotherapies |
| KR20220040476A (ko) * | 2019-08-01 | 2022-03-30 | 메모리얼 슬로안 케터링 캔서 센터 | 개선된 면역치료법을 위한 세포 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5968822A (en) * | 1997-09-02 | 1999-10-19 | Pecker; Iris | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US20040033218A1 (en) * | 2000-12-19 | 2004-02-19 | Oron Yacoby-Zeevi | Use of ecm degrading enzymes for the improvement of cell transplantation |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2007034480A2 (en) * | 2005-09-20 | 2007-03-29 | Carmel-Haifa University Economic Corp. Ltd | Heparanases and splice variants thereof, ponucleotides encoding them and uses thereof |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| US9493740B2 (en) * | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
-
2014
- 2014-03-05 AU AU2014225708A patent/AU2014225708B2/en not_active Expired - Fee Related
- 2014-03-05 US US14/773,330 patent/US20160017302A1/en not_active Abandoned
- 2014-03-05 CN CN201480025440.0A patent/CN105407914A/zh active Pending
- 2014-03-05 CA CA2904236A patent/CA2904236A1/en not_active Abandoned
- 2014-03-05 EP EP14714474.5A patent/EP2964253A1/en not_active Withdrawn
- 2014-03-05 JP JP2015561628A patent/JP2016510594A/ja not_active Ceased
- 2014-03-05 WO PCT/US2014/020936 patent/WO2014138315A1/en not_active Ceased
- 2014-03-05 HK HK16108046.9A patent/HK1220111A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510594A5 (enExample) | ||
| MX2023001878A (es) | Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t. | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX2023012264A (es) | Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico. | |
| EP4219725A3 (en) | Altering gene expression in modified t cells and uses thereof | |
| PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
| WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
| WO2016090034A3 (en) | Methods for b cell preconditioning in car therapy | |
| MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
| MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| CA3045233A1 (en) | Novel t cell receptors and immune therapy using the same | |
| MY192819A (en) | Novel t cell receptors and immune therapy using the same | |
| MY205684A (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| EP4219689A3 (en) | Immune effector cell therapies with enhanced efficacy | |
| CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| MY187624A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
| WO2013040557A3 (en) | Rna engineered t cells for the treatment of cancer | |
| CA2957813C (en) | CD73 BLOCKAGE | |
| MX2020003719A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| EP4279086A3 (en) | Compositions and methods for treating cancer with anti-cd19 immunotherapy | |
| EP4477270A3 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. | |
| EP3998341A3 (en) | Adenoviral vectors |